Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jun;37(6):1364–1366. doi: 10.1128/aac.37.6.1364

In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.

L A Collins 1, G M Eliopoulos 1, C B Wennersten 1, M J Ferraro 1, R C Moellering Jr 1
PMCID: PMC187967  PMID: 8328787

Abstract

In vitro activity of ramoplanin, a cyclic lipoglycopeptide, against 92 vancomycin-resistant gram-positive organisms was evaluated. Ramoplanin demonstrated potent activity against many highly vancomycin-resistant organisms including enterococci (MICs for 90% of strains tested of 0.5 micrograms/ml) and against Lactobacillus spp., Leuconostoc spp., and Pediococcus spp., all of which were inhibited at concentrations of < or = 0.25 micrograms/ml. This drug or a derivative compound merits further investigation as a potential therapeutic agent for infections due to vancomycin-resistant enterococci.

Full text

PDF
1364

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Collins L. A., Malanoski G. J., Eliopoulos G. M., Wennersten C. B., Ferraro M. J., Moellering R. C., Jr In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993 Mar;37(3):598–601. doi: 10.1128/aac.37.3.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Courvalin P. Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother. 1990 Dec;34(12):2291–2296. doi: 10.1128/aac.34.12.2291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eliopoulos G. M., Klimm K., Eliopoulos C. T., Ferraro M. J., Moellering R. C., Jr In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993 Feb;37(2):366–370. doi: 10.1128/aac.37.2.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Handwerger S., Horowitz H., Coburn K., Kolokathis A., Wormser G. P. Infection due to Leuconostoc species: six cases and review. Rev Infect Dis. 1990 Jul-Aug;12(4):602–610. doi: 10.1093/clinids/12.4.602. [DOI] [PubMed] [Google Scholar]
  5. Johnson C. C., Taylor S., Pitsakis P., May P., Levison M. E. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob Agents Chemother. 1992 Oct;36(10):2342–2345. doi: 10.1128/aac.36.10.2342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jones R. N., Barry A. L. In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use. Diagn Microbiol Infect Dis. 1989 May-Jun;12(3):279–282. doi: 10.1016/0732-8893(89)90029-1. [DOI] [PubMed] [Google Scholar]
  7. Mastro T. D., Spika J. S., Lozano P., Appel J., Facklam R. R. Vancomycin-resistant Pediococcus acidilactici: nine cases of bacteremia. J Infect Dis. 1990 May;161(5):956–960. doi: 10.1093/infdis/161.5.956. [DOI] [PubMed] [Google Scholar]
  8. Somner E. A., Reynolds P. E. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob Agents Chemother. 1990 Mar;34(3):413–419. doi: 10.1128/aac.34.3.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Struve J., Weiland O., Nord C. E. Lactobacillus plantarum endocarditis in a patient with benign monoclonal gammopathy. J Infect. 1988 Sep;17(2):127–130. doi: 10.1016/s0163-4453(88)91599-x. [DOI] [PubMed] [Google Scholar]
  10. Yamane N., Jones R. N. In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin. Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):337–345. doi: 10.1016/0732-8893(91)90025-b. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES